In aggregate, these data, especially the prolonged increase in IP10 production observed seven days after the instillation, suggests that CXCL10, along with other pro-inflammatory cytokines, might be a useful biomarker for the classification of BCG-treated bladder cancer patients. This evidence concerns the gene CXCL10 and urinary bladder carcinoma.